Loading cancer entity…
Loading cancer entity…
Clinical trials
68 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03950609 | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04530916 | Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women(WB2020) | completed | Phase 1 / Phase 2 | 58 | Colorado State UniversityOTHER | 1 | Sep 2, 2026 |
| NCT03455075 | Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men | completed | Phase 2 | 92 | Premier ResearchOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03452111 | Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception | completed | Phase 2 | 420 | Premier ResearchOTHER | 7 | Feb 18, 2025 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT00001277 | Studies of Elevated Parathyroid Activity | completed | Phase 2 | 1,553 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00990535 | High Dose Somatostatin Analogues in Neuroendocrine Tumors(HIDONET) | completed | Phase 2 | 28 | Federico II UniversityOTHER | 1 | Oct 7, 2009 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials